Justin Taylor

54PUBLICATIONS
286CO-AUTHORS
Molecular targetsRegenerative medicine (incl. stem cells)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (54)

|Aug 13, 2026
Targeting Bruton's Tyrosine Kinase in CLL: Selectivity, Resistance Mechanisms, and Emerging Therapeutic Strategies.

|Jul 22, 2026
Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors.

|Nov 24, 2025
Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AML.

Mina M Tayari, Helena Gomes Dos Santos, Felipe Beckedorff

|Sep 27, 2025
Resistance Mutations in CLL: Genetic Mechanisms Shaping the Future of Targeted Therapy.

Samantha Sekeres, Erica N Lamkin, Eduardo Bravo

|Jul 30, 2025
XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies.

Traci L Kruer, Ariel Quintana, Hannah Newman

|Jun 18, 2025
XPO1 R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance.

Tulasigeri M Totiger, Wannasiri Chiraphapphaiboon, Yasmine Baca

Pageof 9

Frequent Collaborators

8 joint publications

Rami S Komrokji

8 joint publications

Omar Abdel-Wahab

6 joint publications

Tulasigeri Totiger

6 joint publications

Zhuoer Xie